-
公开(公告)号：US20190337921A1
公开(公告)日：2019-11-07
申请号：US16349508
申请日：2017-11-22
发明人： Mark Bock , Ming-Hong Hao , Manav Korpal , Vijay Kumar Nyavanandi , Xiaoling Puyang , Susanta Samajdar , Peter Gerard Smith , John Wang , Guo Zhu Zheng , Ping Zhu , Lorna Helen Mitchell , Nicholas Larsen , Nathalie Rioux
IPC分类号： C07D401/06 , C07D209/08 , C07D401/14 , A61P35/00
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：US11083722B2
公开(公告)日：2021-08-10
申请号：US16493931
申请日：2018-03-16
IPC分类号： A61K31/519 , A61K31/4427 , A61K31/415 , A61P35/00 , A61K31/445 , A61K45/06
摘要： Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.
-
公开(公告)号：US20200255415A1
公开(公告)日：2020-08-13
申请号：US16349479
申请日：2017-11-22
发明人： Mark Bock , Ming-Hong Hao , Manav Korpal , Vijay Kumar Nyavanandi , Xiaoling Puyang , Susanta Samajdar , Peter Gerard Smith , John Wang , Guo Zhu Zheng , Ping Zhu , Lorna Helen Mitchell , Nicholas Larsen , Nathalie Rioux , Sudeep Prajapati , Dominic Reynolds , Morgan O'Shea , Thiwanka Samarakoon
IPC分类号： C07D413/14 , A61P35/00 , C07D231/56 , C07D401/10 , C07D401/14 , C07D401/12 , C07D413/12 , C07D403/10
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
-
搜索结果
3 条记录 (耗时 0.016 秒)
